Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 4,019 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Healthy Volunteers
Interventions: E2086, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Dementia
Interventions: Hand feeding techniques; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 60 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 11
States / cities: Apex, North Carolina • Chapel Hill, North Carolina • Durham, North Carolina + 1 more

Conditions: Early Breast Cancer
Interventions: Cyclophosphamide, Doxorubicin, Docetaxel, Paclitaxel, Pertuzumab IV, FDC of Pertuzumab and Trastuzumab SC, Trastuzumab IV, Trastuzumab SC, Surgery, Post-operative Radiotherapy, Hormone Therapy; Drug · Procedure · Radiation
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 4
States / cities: Rockville, Maryland • Farmington, New Mexico • Charlotte, North Carolina + 1 more

Conditions: Type 1 Diabetes
Interventions: Teplizumab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: Not listed
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 24
States / cities: Little Rock, Arkansas • San Francisco, California • Aurora, Colorado + 19 more

Conditions: Covid-19, Cognitive Impairment
Interventions: Speed of Processing Training, Instrumental Activities of Daily Living Shaping, Transfer Package from CI Therapy, Usual Care; Behavioral · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: HIV Infections
Interventions: VH4004280, Placebo, Midazolam; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Solid Tumor, Advanced Solid Tumor
Interventions: NL-201, Pembrolizumab Injection [Keytruda]; Drug
Lead sponsor: Neurogene Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: New York, New York • Portland, Oregon • Houston, Texas + 1 more

Conditions: Stroke
Interventions: Cognitive Rehabilitation, Occupational Therapy; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Malocclusion
Interventions: EXD-959 Bracket System; Device
Lead sponsor: 3M; Industry
Eligibility: 11 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 5
States / cities: Culver City, California • Wellington, Florida • Northfield, Minnesota + 2 more

Conditions: Pulmonary Embolism, Pulmonary Hypertension, Thromboembolism, Right Ventricular Dysfunction
Interventions: Alteplase, EKOS; Drug · Device
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years to 89 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Bay Shore, New York • Queens, New York

Conditions: Healthy Volunteer
Interventions: Venetoclax; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Grayslake, Illinois • Austin, Texas

Conditions: Papillomavirus Vaccines
Interventions: Brief training, Parent-targeted motivational aids, Healthcare access; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 8 Years to 99 Years
Enrollment: 4,630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Glioma
Interventions: rhIL-7-hyFc, Placebo, Temozolomide, Radiation therapy; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Solid Tumor Cancer
Interventions: X-PACT; Combination Product
Lead sponsor: Immunolight, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Charlotte, North Carolina • Durham, North Carolina + 1 more

Conditions: Parkinson Disease
Interventions: Levodopa, Clinical DBS Setting, Sham DBS, DBS Setting Maximizing Prefrontal Activation, DBS Setting Minimizing Prefrontal Activation; Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 45 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions: Concizumab; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: Male only
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 7
States / cities: Orange, California • Atlanta, Georgia • Indianapolis, Indiana + 4 more

Conditions: Brain and Central Nervous System Tumors
Interventions: Induction Chemotherapy, Low-Risk Therapy, High-Risk Therapy, Intermediate-Risk Therapy; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 5 Years
Enrollment: 293 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2029
U.S. locations: 5
States / cities: Palo Alto, California • San Diego, California • Saint Paul, Minnesota + 2 more

Conditions: Sleep Problem, Insomnia, Pediatric Cancer
Interventions: Survivor-SHIP; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 5 Years to 12 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR
Interventions: VIR-5525, Pembrolizumab; Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Scottsdale, Arizona • Houston, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: Tetrathiomolybdate; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cardiovascular Diseases
Interventions: Eggs - 2 per day for breakfast, 1 packet of oatmeal per day; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 18 Years to 30 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Advanced Solid Tumor, Gynecologic Cancer, Breast Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Lung Adenocarcinoma, Pancreatic Cancer, Head and Neck Cancer
Interventions: PY159 Single agent dose level 1, PY159 Single agent dose level 2, PY159 Single agent dose level 3, PY159 Single agent dose level 4, PY159 Single agent dose level 5, PY159 Single agent dose level 6, PY159 Single agent dose level 7, PY159/Pembrolizumab Combination dose level 1, PY159/Pembrolizumab Combination dose level 2, PY159/Pembrolizumab Combination dose level 3, PY159/Pembrolizumab Combination dose level 4, PY159 Single agent dose expansion cohort, PY159/Pembrolizumab Combination dose expansion cohort 1, PY159/Pembrolizumab Combination dose expansion cohort 2, PY159/Pembrolizumab Combination dose expansion cohort 3, PY159/Pembrolizumab Combination dose expansion cohort 4, PY159/Pembrolizumab Combination dose expansion cohort 5, PY159/Pembrolizumab Combination dose expansion cohort 6; Drug
Lead sponsor: Ikena Oncology; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: AZD4831, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 21
States / cities: Alexander City, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more

Conditions: Leukemia, Lymphocytic, Acute, AML, MDS
Interventions: Stem Cell Transplant, Busulfan, Cyclophosphamide, Melphalan, G-CSF, ATG; Procedure · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 35 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

Comparison of Hand Feeding Techniques for Persons With Dementia

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Description of Patients With Type 1 Diabetes Treated With Teplizumab

Improving Thinking in Everyday Life After Covid-19

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer

Cognitive Priming for Stroke Tele-rehabilitation

EXD-959 Orthodontic Brackets and EXD-961 Related Instruments Trial

Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE

A Study to Evaluate the Bioavailability and Food Effects of Oral Venetoclax New Tablet Formulation 2.0 in Healthy Adult Female Participants

ReMARK: Addressing Disparities in Rural HPV-related Cancer Prevention

rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors

Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma

Survivor-Sleep Health Information Program

Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer

Eggs as Part of a Healthy Breakfast

A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%

Stem Cell Transplantation for Hematological Malignancies